Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
about
Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).
P2860
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Weight-based dosing of Yttrium ...... y B-cell non-Hodgkin lymphoma.
@ast
Weight-based dosing of Yttrium ...... y B-cell non-Hodgkin lymphoma.
@en
type
label
Weight-based dosing of Yttrium ...... y B-cell non-Hodgkin lymphoma.
@ast
Weight-based dosing of Yttrium ...... y B-cell non-Hodgkin lymphoma.
@en
prefLabel
Weight-based dosing of Yttrium ...... y B-cell non-Hodgkin lymphoma.
@ast
Weight-based dosing of Yttrium ...... y B-cell non-Hodgkin lymphoma.
@en
P2093
P356
P1476
Weight-based dosing of Yttrium ...... y B-cell non-Hodgkin lymphoma.
@en
P2093
Arturo Molina
Christos Emmanouilides
Dan H Silverman
Gregory A Wiseman
Mohamed Darif
Peter S Conti
Russell J Schilder
Thomas E Witzig
P304
P356
10.3816/CLM.2007.N.035
P50
P577
2007-09-01T00:00:00Z